Abstract
: Allergic alveolitis/hypersensitive pneumonitis (EAA/HP) in its acute phase and allergic asthma in the chronic phase can be triggered by pigeon allergies. These allergies induce an immune response marked by elevated immunoglobulin E (IgE) levels, which block FCER-1 receptors on mast cells. This blockage prevents the release of histamine, leukotrienes C4, and prostaglandin D4, responsible for smooth muscle contraction and vascular leakage. Additionally, IgE can block FceRI receptors on basophils, forming IgE-FC complexes and stimulating CD23 and HEK-293 cells, while also increasing lung alveolar inflammation. Combining Cε2 with omalizumab can lower free IgE levels and block FceRI and CD23. Chronic pigeon allergies can be managed with treatments such as monoclonal antibodies, inhaled corticosteroids (ICS), and Cromolyn, either alone or in combination. Monoclonal antibodies target molecules that trigger allergic reactions, reducing symptoms. Inhaled corticosteroids help control airway inflammation and sensitivity, easing respiratory issues. Cromolyn, available as nasal sprays or eye drops, prevents the release of inflammatory substances, reducing symptoms like sneezing and itching. Combining these treatments can improve symptom management by addressing different aspects of the allergic reaction. Moreover, treatments targeting the thymic stromal lymphopoietin (TSLP) pathway are showing promise for reducing skin inflammation in conditions like atopic dermatitis (AD). It is crucial to consult a healthcare professional to determine the most appropriate treatment plan.